Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase 1 Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients With Bulky Stage III Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01797471
• Other study ID #: 20100446
• Status: Terminated
• Phase: N/A
• First received: February 20, 2013
• Last updated: November 28, 2017
• Start date: March 2013
• Est. completion date: November 6, 2013

Study information

• Verified date: November 2017
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent chemotherapy and radiation delivered over 6 weeks in patients with bulky stage III non-small cell lung cancer in the setting of a single-arm phase I clinical trial. The investigators hypothesize that the addition of a one-time single fraction of LEAD radiation is safe and feasible, and will not result in additional toxicity above that expected with standard-dose concurrent chemotherapy and radiation alone.

Description:

Paarticipants will receive a single fraction of LEAD radiation on day 1, followed one day later by conventionally fractionated concurrent chemoradiation consisting of 60 Gy of radiation delivered to involved sites of disease and a platinum doublet.

The investigational radiation treatment, a single fraction of LEAD radiation, is to be followed by conventionally fractionated radiation delivered concurrently with a standard chemotherapy regimen for stage III non-small cell lung cancer. The following day, patients will begin concurrent chemotherapy and radiation. Chemotherapy will be delivered under the management of the treating medical oncologist. Chemotherapy must be a platinum doublet. Carboplatin and cisplatin are both considered acceptable platinum agents. The use of cisplatin over carboplatin is strongly encouraged, unless the patient has a contraindication to cisplatin. The second agent will be at the discretion of the treating medical oncologist; in the current era, chemotherapy agents are tailored to each patient based on tumor histology, as well as comorbidities that dictate the tolerance of certain chemotherapeutic agents. Chemotherapy will be delivered concurrently throughout radiation therapy, beginning on day 2 of the treatment protocol and on the same day as the start of standard-dose radiation. Weekly regimens or regimens delivered every 3 weeks are acceptable. Additional cycles of consolidation chemotherapy are encouraged and will be given at the discretion of the treating medical oncologist.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: November 6, 2013
• Est. primary completion date: May 31, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have histologically or cytologically documented stage III non-small cell lung cancer including squamous cell, adenocarcinoma, large cell carcinoma and poorly differentiated non-small cell lung cancer.

2. Patients must have a minimum of 4 cm of measurable disease in any one continuous dimension as seen on diagnostic CT scan.

3. Pulmonary function tests with forced expiratory volume in 1 second (FEV1) =1.45 liters/second.

4. Patients must be 21 years of age or older. There is no maximum age restriction.

5. Patients must have a Zubrod performance status of 0 or 1.

6. Patients must have normal organ and marrow function as defined below:

• leukocyte > 3,000/:I

• absolute neutrophil count >1,500/:I

• platelets >100,000/:I

• bilirubin within normal institutional limits

• Aspartate transaminase (AST/SGOT)/Alanine transaminase (ALT/SGPT) 2.5 X institutional upper limit of normal

• Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.

7. Patients must have weight loss = 10% over the past three months.

8. Women of child-bearing potential and men will be asked to use adequate contraception.

9. Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Patients may not have had prior thoracic radiation at any time, or prior chemotherapy for the study cancer at any time.

2. Patients may not be receiving any other investigational agents for the study cancer.

3. Patients may not have evidence of brain metastases on baseline CT scan or MRI.

4. Patients may not have measurable gross disease in the thorax <4 cm in any one continuous dimension.

5. Patients may not have a cytologically positive pleural effusion.

6. Patients may not have a prior invasive malignancy (unless disease-free for at least 3 years).

7. Patients may not have had surgical resection of the present cancer.

8. Women who are pregnant or breastfeeding will be excluded.

9. Patients must not have any co-morbidity with life expectancy = 6 months, or any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

10. Patients must not have severe lung disease defined by a history of severe chronic obstructive pulmonary disease (COPD) requiring 3 or more hospitalizations over the past year, or history of interstitial pneumonitis.

11. Patients must not have any concurrent active malignancy.

12. Patients must not have evidence of metastatic disease.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer
• NSCLC

Intervention

Radiation:
• Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Treatment-related Toxicity in Study Participants	Rate of treatment-related toxicity (serious adverse events, adverse events, etc.) in study participants. Toxicity will be assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The two toxicities that will be monitored as primary endpoints are esophagitis and pneumonitis.	Up to 12 months
Secondary	Rate of Study Participants Achieving Complete or Partial Response Via CT RECIST Response Criteria	Number of subjects achieving complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria on CT Scan: CR: Complete disappearance of all disease. No new lesions. No disease related symptoms. Normalization of markers and other abnormal lab values. All disease must be assessed using the same technique as baseline.; PR: Greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions.	Assessed up to 2 years
Secondary	Rate of Study Participants Achieving Complete or Partial Response Via PET Response Criteria	Rate of subjects achieving complete response (CR) or partial response (PR) as detected by positron emission tomography (PET) Scan: CR is defined as no residual focal fluorodeoxyglucose (FDG) uptake or decrease in average FDG uptake by more than 80% in all tumor manifestations.; PR is defined as standardized uptake value (SUV) decrease by 0 - 80%.	Assessed up to 2 years
Secondary	Rate of Loco-regional Failure in Study Participants	Rate of loco-regional failure in study participants. Loco-regional failure is defined as any evidence of disease progression within the primary primary tumor or regional lymph nodes, detected by any method.	Assessed up to 2 years
Secondary	Progression-Free Survival (PFS)	Rate of progression-free survival (PFS). PFS is defined as the length of time from date of treatment initiation until date of documented disease progression or death from any cause, with censoring of patients who are lost to follow-up.	Assessed up to 2 years
Secondary	Overall Survival (OS)	Rate of overall survival (OS) in study participants. Overall survival is defined as the length of time from the date of treatment initiation until the date of death from any cause.	Assessed up to 2 years